CTOs on the Move

Ambrx

www.ambrx.com

 
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx`s protein engineering technology.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.ambrx.com
  • 10975 North Torrey Pines Road
    La Jolla, CA USA 92037
  • Phone: 858.875.2400

Executives

Name Title Contact Details

Funding

Ambrx raised $45M on 08/05/2016
Ambrx raised $200M on 11/09/2020

Similar Companies

Vital Pharma

Vital Pharma Inc. is a West Palm Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DSM PTG

DSM PTG, Inc is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stowers Resource Management

Stowers Resource Management is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Joslin Diabetes Center

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 11 NIH-designated Diabetes Research Centers in the U.S.

Adverum

Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.